Thomas Catinazzo, Chief Financial Officer at Relay Therapeutics, Inc. (RLAY), sold 113,480 shares at $4.63 ($517K) on 2025-01-28, disclosed to the SEC on 2025-01-30.
Scheduled sale ($517k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.63 | 2,283 | $11K | 2.0% |
| 2 | $4.63 | 33,753 | $156K | 30.3% |
| 3 | $4.63 | 33,753 | $156K | 30.3% |
| 4 | $4.55 | 2,109 | $10K | 1.9% |
| 5 | $4.42 | 20,791 | $92K | 17.8% |
| 6 | $4.42 | 20,791 |
| $92K |
| 17.8% |
| Total | $4.55 avg | 113,480 | $517K | 100% |
| Filing → |
| RLAY | SELL | 2026-08-18 | $350K | — | Filing → |
| RLAY | SELL | 2026-07-30 | $27K | — | Filing → |
| RLAY | SELL | 2026-07-08 | $331K | — | Filing → |